ALB and cancer: In summary, we develop a novel nano-drug by using HSA to load atovaquone, and demonstrate that this nano-drug enhances the efficacy of PD-1 blockade immunotherapy by alleviating tumor hypoxia microenvironment, thereby providing a potential strategy for cancer therapy.